Hospital admissions and mortality in AIDS patients in the HAART era. Where are we heading?;Ingresos hospitalarios y mortalidad en pacientes con sida en la era TARGA: ¿Hacia dónde vamos?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 3, 2004, Pages 129-132

  Iribarren, José Antonio ^a   González García, Juan ^b  

^a HOSPITAL DONOSTIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DIAGNOSTIC TEST; EDITORIAL; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; MORTALITY;

EID: 11144355043     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058018     Document Type: Editorial

References (54)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. th World AIDS Conference. Ginebra, 28 Junio-3 Julio de 1998. Abstract 12276.
3. Torti C, Casari S, Palvarini L, Quiros-Roldán E, Moretti F, Leone L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 2003;65:261-7.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
5. Domingo P, Guardiola JM, Ris J, Nolla J. The impact of new antiretroviral regimes on HIV-associated hospital admissions and deaths. AIDS 1998;26:529-30.
6. Pérez-Hoyos S, Del Amo J, Muga R, Del Romero J, García de Olalla P, Guerrero R, et al. Effectiveness of highly active antirretroviral therapy in Spanish cohorts of HIV seroconverters: Differences by transmission category. AIDS 2003;17:353-9.
7. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EurosSIDA study: An observational study. Lancet 2003;362:22-9.
8. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Costs and Services Utilization Study. JAMA 1999;281:2305-15.
9. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003;188:1164-70.
10. Wood E, Montaner JS, Bangsberg DR, Tyndall MW, Strathdee SA, O'Shaughnessy MV, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003;17:2419-27.
11. Casseb J, Orrico GS, Feijo RD, Guaracy L, Medeiros LA. Lack of prior antiretroviral therapy is associated with increased mortality among hospitalized patients with AIDS in Sao Paulo, Brazil. AIDS Patient Care STDS 2001;15:271-5.
12. Iribarren JA, Jimeno B, Camino X, Pascual L, Landa MA, Izco A, et al. "Consecuencias asistenciales de los nuevos tratamientos: ¿somos suficientemente efectivos?" En: Usietto R, editor. SIDA. Hacia un tratamiento integral. Médico, biológico y social. CESA Ediciones. Depósito Legal: M-7386-2001.
13. Farinpour R, Miller EN, Satz P, Selnes OA, Cohen BA, Becker JT, et al. Psychosocial risk factors of HIV morbidity and mortality: Findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol 2003;25:654-70.
14. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002;16:2065-72.
15. McFarland W, Chen S, Hsu L, Schwarcz S, Katz M. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr 2003;33:96-103.
16. Marimoutou C, Poizot-Martin I, Loundou AD, Cassuto JP, Obadia Y, Groupe d'etude MANIF 2000. Causes of hospitalization and death in the MANIF 2000 cohort, composed of HIV-infected patients contaminated by intravenous drug use, 1995-1999. Presse Med 2003;32:587-94.
17. Teira R, Lizarralde E, Muñoz P, Zubero Z, Baraia-Etxaburu J, Santamaría JM. Estudio transversal sobre las características clínicas y epidemiológicas de la infección por el virus de la inmunodeficiencia humana en gitanos y otras minorías en Bilbao. Med Clin (Barc) 2002;119:653-6.
18. San-Andres FJ, Rubio R, Castilla J, Pulido F, Palao G, De Pedro I, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003;36:1177-85.
19. Tashima KT, Hogan JW, Gardner LI, Korkontzelou C, Schoenbaum EE, Schuman P, et al. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clin Infect Dis 2001;33:2055-60.
20. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003;17:711-20.
21. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
22. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003;139:810-6.
23. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10.
24. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
25. Iribarren JA, Arrizabalaga J, Lorenzo JM, Sarasqueta C, Rodríguez F, Von Wichmann MA, et al. Clinical and epidemiological characteristics of patients newly diagnosed of HIV infection in the last six years. XIV International AIDS Conference, Barcelona, July 7-12 2002, Abstract C10675.
26. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: Consequences for AIDS incidence. AIDS 2002;16:1945-51.
27. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA Study. J Infect Dis 2001;183:1290-4.
28. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-29.
29. Reus S, Portilla J, Gimeno A, Sánchez-Payá J, García-Henarejos JA, Martínez-Madrid O, et al. Predictores de progresión y muerte en pacientes con infección avanzada por el VIH en la era de los tratamientos antirretrovirales de gran actividad. Enf Infecc Microbiol Clin 2004;22(3):138-45.
30. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
31. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-31.
32. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003;17:2191-9.
33. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13.
34. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
35. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
36. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-9.
37. Von Wichmann MA, Arevalo S, Zapata E, Rodrígruez F, Arrizabalaga J, Iribarren JA, et al. Survival in HIV+ patients with viral hepatitis after ascites has developed. 43rd ICAAC, Chicago, September 14-17 2003; Abstract V-782.
38. nd IAS Conference on HIV Pathogenesis and treatment, París, july 2003; abstract 985.
39. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 2004;38:128-33.
40. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:365-72.
41. Martín-Carbonero L, Soriano V, Valencia E, Garcí a-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-71.
42. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-9.
43. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000;24:211-7.
44. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
45. Camino X, Iribarren JA, Arrizabalaga J, Rodríguez F, Von Wichmann AM. Causas de mortalidad de los pacientes infectados por el virus de inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad. Enferm Infecc Microbiol Clin 2001;19:85-6.
46. Milinkovic A, Martínez E, De Lazzari E, Buira E, Pérez-Cuevas JB, Blanco JL, et al. Trends in mortality anda causes of death in HIV-infected persons receiving highly active antiretroviral therapy. XIV International AIDS Conference, Barcelona, July 7-12 2002, Abstract TuPeC4758.
47. Rodríguez-Vidigal FF, Habernau A. Motivo de ingreso en pacientes infectados por el virus de la inmunodeficiencia humana en un área rural. Papel de la hepatopatía crónica. Enf Infecc Microbiol Clin 2004;22(3):134-7.
48. Dronda F, Moreno S, Pérez-Elias MJ, Casado JL, Antela A, Moreno A. Vascular disease in HIV-infected patients: A comparative study of two different therapeutic periods (1994-1997 versus 1998-2000). AIDS 2002;16:1971-3.
49. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-7.
50. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
51. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 Clinic in the era oh highly active antiretroviral therapy: A 5-year cohort study. J Acquir Immune Def Syndr 2003;33:321-8.
52. Wood E, Montaner JSG, Bansberg DR, Tyndall MW, Strathdee SA, O'Shaughnessy MV, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003;17:2419-27.
53. Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS 2003;17:283-90.
54. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enferm Infecc Microbiol Clin 2002;20:244-303.